Novamab

company

About

Novamab focuses on the research and development of new nanobodies.

  • 51 - 100

Details

Last Funding Type
Series A
Last Funding Money Raised
¥100M
Industries
Biotechnology,Pharmaceutical,Product Research,Therapeutics
Founded date
Jan 1, 2017
Number Of Employee
51 - 100
Operating Status
Active

Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platform and a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
¥100M
Novamab has raised a total of ¥100M in funding over 2 rounds. Their latest funding was raised on Mar 12, 2021 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 12, 2021 Series A ¥100M 2 Tianhui Chuangtou Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Novamab is funded by 2 investors. Tianhui Chuangtou and Tigeryeah Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Tianhui Chuangtou Yes Series A
Tigeryeah Capital Series A